Open-label, Randomized, Crossover Clinical Trials for Single Oral Dose of 60mg Fimasartan and Single IV Infusion of 30mg Fimasartan to Evaluate the Absolute Bioavailability of Kanarb Tablet (Fimasartan) in Healthy Subjects

Trial Profile

Open-label, Randomized, Crossover Clinical Trials for Single Oral Dose of 60mg Fimasartan and Single IV Infusion of 30mg Fimasartan to Evaluate the Absolute Bioavailability of Kanarb Tablet (Fimasartan) in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Jul 2016

At a glance

  • Drugs Fimasartan (Primary) ; Fimasartan (Primary)
  • Indications Hypertension
  • Focus Pharmacokinetics
  • Most Recent Events

    • 15 Mar 2015 Status changed from recruiting to completed according to an abstract published at the 116th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
    • 28 Aug 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top